Varian affiliate VMS Deutschland Holdings intends to make a voluntary public tender offer to all MeVis shareholders to acquire their non-par value registered shares at a price of €17.50 per share, which is expected to be around €30m.

Varian Medical Systems CEO Dow Wilson said: "Early detection and treatment of tumors can have a significant impact on outcomes for cancer treatment and we are looking forward to the prospect of adding advanced software for early cancer detection to our product portfolio."

MeVis develops advanced software for the analysis and processing of image data, which is marketed to imaging equipment manufacturers for screening breast cancer as well as lung, liver, prostate, and colon cancer.

According to Varian, the acquisition will also include the MeVisLab software platform, a research and development environment facilitating the efficient realization of tailored software solutions using a rapid prototyping approach.

The MeVis team would continue to develop cancer screening and image processing applications at its current facility in Breme, following the acquisition.

Varian Imaging Components president Sunny Sanyal said: "We believe we can integrate MeVis technology to offer our customers smarter flat-panel detectors and imaging workstations for cancer screening."

Varian noted that its imaging components business is a global provider of X-ray tubes, flat-panel detectors, and image processing software and workstations for digital imaging.